Last reviewed · How we verify

3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency — Treatment Landscape & Competitive Intelligence

3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating 3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cholbam CHOLIC ACID Mirum Bile Acid [EPC] G-protein coupled bile acid receptor 1 2015-01-01
Cholbam Cholbam Mirum Pharmaceuticals, Inc. G-protein coupled bile acid receptor 1, Bile acid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Mirum · 1 drug in 3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency
  2. Mirum Pharmaceuticals, Inc. · 1 drug in 3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in 3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency:

Cite this brief

Drug Landscape (2026). 3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/3-beta-hydroxy-delta-5-c27-steroid-dehydrogenase-deficiency. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing